Skip to main content
Fig. 2 | Critical Care

Fig. 2

From: Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial

Fig. 2

The primary endpoint and extravascular lung water index (EVLWi) over time, stratified by randomization group. Boxplot (A) depicting the distribution of the change in EVLWi in the imatinib group versus the placebo group between baseline (day 1) and day 4. Scatterplot (B) depicting the dynamic changes of the EVLWi per treatment day in the imatinib group versus the placebo group from day 1 to day 7

Back to article page

Critical Care

ISSN: 1364-8535